Status:
ACTIVE_NOT_RECRUITING
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Lead Sponsor:
Eli Lilly and Company
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development....
Eligibility Criteria
Inclusion
- Have a diagnosis of HS for at least 12 months.
- Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
- Have an (abscess plus inflammatory nodule) count of at least 5.
- Agree to use topical antiseptics daily.
- Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion
- Have more than 20 draining fistulae.
- Have had surgical treatment for HS in the last 4 weeks before randomization.
- Have an active skin disease or condition, that could interfere with the assessment of HS.
- Have a current or recent acute, active infection.
- Are immunocompromised.
- Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Key Trial Info
Start Date :
October 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2026
Estimated Enrollment :
352 Patients enrolled
Trial Details
Trial ID
NCT06046729
Start Date
October 23 2023
End Date
August 1 2026
Last Update
October 16 2025
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006
2
Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix, Arizona, United States, 85008
3
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States, 72117
4
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States, 72758